CGAS and neoplasm: PRMT1 acts as a suppressor of tumor immune surveillance in a cGAS (cyclic GMP-AMP synthase)-dependent manner through methylating cGAS at the conserved R133 residue on its N-terminus, and then blocking cGAS DNA sensing signaling, thus promoting tumor immune evasion [106].